Since genetic EC‐S1pr1 overexpression in vitro can inhibit cardiomyocyte hypertrophy and myofibroblast accumulation, we next tested whether pharmacological activation of S1pr1 has a beneficial effect on pathological cardiac remodelling during chronic heart failure. This evidence concerns the gene S1PR1 and congestive heart failure.